Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/02/27/2836408/0/en/BioAegis-Therapeutics-Unveils-Upcoming-Clinical-Study-of-Gelsolin-an-Immune-Regulator-as-a-Treatment-for-Patients-with-Acute-Respiratory-Distress-Syndrome-ARDS.html
https://www.globenewswire.com//news-release/2023/10/16/2761017/0/en/BioAegis-Therapeutics-Awarded-20-Million-BARDA-DRIVe-Contract-to-Advance-Gelsolin-an-Immune-Regulator-as-a-Treatment-for-Patients-with-Acute-Respiratory-Distress-Syndrome-ARDS.html
https://www.globenewswire.com/news-release/2023/05/10/2665420/0/en/BioAegis-Therapeutics-to-Sponsor-a-Webinar-Below-the-Eyes-of-the-Hippopotamus-The-Expanding-Spectrum-of-Auto-and-Hyper-Inflammatory-Diseases.html
https://www.globenewswire.com/news-release/2023/04/13/2646635/0/en/BioAegis-Therapeutics-Announces-Two-Studies-Exploring-the-Role-of-Inflammation-Regulator-Gelsolin-in-Type-2-Diabetes.html
https://www.globenewswire.com/news-release/2023/01/26/2596413/0/en/BioAegis-Therapeutics-Announces-FDA-Clearance-of-IND-for-its-Inflammation-Regulator-Protein-Gelsolin-for-the-Treatment-of-ARDS.html
https://www.globenewswire.com//news-release/2023/01/06/2584647/0/en/BioAegis-Leverages-Gelsolin-s-Broad-Therapeutic-Applicability-by-Expanding-into-Multiple-Inflammatory-Diseases.html
https://www.globenewswire.com//news-release/2022/12/05/2567799/0/en/BioAegis-Therapeutics-Highlights-Recent-Article-on-its-Novel-Host-Directed-Protein-Plasma-Gelsolin-for-Inflammatory-Diseases.html
https://www.globenewswire.com/news-release/2022/03/22/2407310/0/en/BioAegis-Therapeutics-Completes-22-Million-Institutional-Sale-of-Equity-in-a-Non-Brokered-Transaction.html
https://www.globenewswire.com/news-release/2022/02/17/2387654/0/en/BioAegis-Therapeutics-Announces-Appointment-of-Two-New-Corporate-Board-Members.html
https://www.globenewswire.com/news-release/2021/10/29/2323913/0/en/BioAegis-Therapeutics-to-Present-Conquering-Pneumonia-and-Systemic-Inflammation-with-a-Human-Protein-at-the-MACRO-Trends-Investor-Conference-in-Belgium.html